Adam Hacking

Adam Hacking is an accomplished professional in the field of biomedical engineering with extensive experience in both leadership and research. Currently serving as Study Director at Neuralink since October 2022, Adam previously founded and led RegenX as CEO, focusing on anti-aging and tendon repair treatments. Adam held significant roles at ROM Technologies Inc. as VP Engineering, where a cloud-enabled rehabilitation system was developed, and at Langholm Consulting as Principal, providing services for medical device development and pre-clinical testing. Adam's earlier positions include Chief Scientific Officer at Oxford Performance Materials and Principal Investigator at Massachusetts General Hospital, establishing a laboratory dedicated to orthopedic research. With a strong educational background featuring post-doctoral fellowships and a PhD in Biomedical Engineering from McGill University, Adam Hacking's expertise continues to influence advancements in the medical field.